NOMAD POWER SOLUTIONS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
NOMAD POWER SOLUTIONS, INC. (NMAD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.82% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-31
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-03-31 was 1.23%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 3.82%, a 10.96% decline from fiscal 2024.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.29%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.63%, a 221.24% increase from fiscal 2021.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.13%, a 264.52% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.82% 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 3.82% 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | 4.29% 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 4.29% 10-Q · filed 2025-11-12 | |||
| 2022-12-31 | 3.63% 10-K · filed 2024-03-19 | |||
| 2021-12-31 | 1.13% 10-K · filed 2022-03-21 | |||
| 2020-12-31 | 0.31% 10-K · filed 2022-03-21 | |||
| 2020-09-30 | 0.31% 10-Q · filed 2020-11-10 | |||
| 2019-12-31 | 1.85% 10-K · filed 2021-03-26 | |||
| 2019-09-30 | 1.85% 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | 3.01% 10-K · filed 2020-03-25 | |||
| 2018-09-30 | 3.01% 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | 2.47% 10-K · filed 2018-03-23 | |||
| 2017-09-30 | 1.53% 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 1.53% 10-Q · filed 2017-08-04 | |||
| 2016-12-31 | 1.93% 10-K · filed 2018-03-23 | |||
| 2016-09-30 | 1.31% 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | 1.23% 10-Q · filed 2017-08-04 | |||
| 2016-03-31 | 1.23% 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 1.66% 10-K · filed 2017-03-29 | |||
| 2015-09-30 | 1.66% 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | 1.66% 10-Q · filed 2016-08-10 | |||
| 2014-12-31 | 1.75% 10-K · filed 2016-03-28 | |||
| 2014-09-30 | 1.67% 10-Q · filed 2015-11-10 | |||
| 2014-06-30 | 1.67% 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |